|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021747,
umls-concept:C0023981,
umls-concept:C0034656,
umls-concept:C0443252,
umls-concept:C0444956,
umls-concept:C0524910,
umls-concept:C0871261,
umls-concept:C1623038,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2003941,
umls-concept:C2603343,
umls-concept:C2911692
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1999-2-11
|
|
pubmed:abstractText |
The long-term response to alpha-Interferon in HCV-related chronic liver diseases is disappointing. A randomized controlled trial was conducted to investigate: 1) if doubling the standard regimen of 3 MU recombinant alpha 2b-interferon thrice weekly for one year could improve the long-term response, and 2) the efficacy of these two schedules in cirrhotic patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1125-8055
|
|
pubmed:author |
pubmed-author:AddariiFF,
pubmed-author:AmitranoLL,
pubmed-author:AscioneAA,
pubmed-author:BicegliaOO,
pubmed-author:BullT BTB,
pubmed-author:CanestriniCC,
pubmed-author:De LucaMM,
pubmed-author:Di CostanzoG GGG,
pubmed-author:FaleoDD,
pubmed-author:ForteG BGB,
pubmed-author:GigliottiTT,
pubmed-author:LongoGG,
pubmed-author:MannoM LML,
pubmed-author:RaimondoGG,
pubmed-author:RoccaFF,
pubmed-author:TillmannH LHL,
pubmed-author:VinelliFF
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
517-23
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9836109-Adult,
pubmed-meshheading:9836109-Aged,
pubmed-meshheading:9836109-Alanine Transaminase,
pubmed-meshheading:9836109-Antiviral Agents,
pubmed-meshheading:9836109-Dose-Response Relationship, Drug,
pubmed-meshheading:9836109-Drug Administration Schedule,
pubmed-meshheading:9836109-Female,
pubmed-meshheading:9836109-Follow-Up Studies,
pubmed-meshheading:9836109-Hepatitis C, Chronic,
pubmed-meshheading:9836109-Humans,
pubmed-meshheading:9836109-Interferon Type I,
pubmed-meshheading:9836109-Liver Cirrhosis,
pubmed-meshheading:9836109-Male,
pubmed-meshheading:9836109-Middle Aged,
pubmed-meshheading:9836109-Prospective Studies,
pubmed-meshheading:9836109-RNA, Viral,
pubmed-meshheading:9836109-Recombinant Proteins,
pubmed-meshheading:9836109-Treatment Outcome
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Efficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: prospective randomized multicentre study.
|
|
pubmed:affiliation |
Liver Pathophysiology Unit, A. Cardarelli Hospital, Napoli, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
